51674-77-2

Usage

Uses

Used in Pharmaceutical Industry:
Pyrido[3,2-d]pyrimidine, 4-chlorois utilized as a key building block in the synthesis of biologically active molecules. It plays a crucial role in the development of new drugs, contributing to the advancement of medicinal chemistry by providing a structural framework that can be modified to create a variety of pharmaceutical agents with different therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, Pyrido[3,2-d]pyrimidine, 4-chloroserves as a fundamental component in the creation of pesticides. Its chemical structure allows for the design of compounds that can effectively control pests and diseases in agriculture, thereby enhancing crop protection and contributing to increased agricultural productivity.
Used in Antitumor Research:
Pyrido[3,2-d]pyrimidine, 4-chlorohas been investigated for its potential antitumor properties. It is studied for its capacity to interact with biological targets and exhibit inhibitory effects on tumor growth, making it a promising candidate for further research and development in oncology.
Used in Antiviral Research:
Additionally, Pyrido[3,2-d]pyrimidine, 4-chloro- has shown potential in antiviral applications. Research into its antiviral properties aims to understand how it can be leveraged to inhibit viral replication and infectivity, offering new avenues for the treatment of viral diseases.
Overall, Pyrido[3,2-d]pyrimidine, 4-chlorois a versatile chemical entity with broad implications in various fields, particularly医药 in the development of therapeutic agents and protective chemicals in healthcare and agriculture.

InChI:InChI=1/C7H4ClN3/c8-7-6-5(10-4-11-7)2-1-3-9-6/h1-4H

Upstream product

• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 37538-67-3 4-hydroxy-pyrido[3,2-d]pyrimidine 
• 1462-86-8 3-amino-pyridine-2-carboxylic acid 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 50608-99-6 3-amino-pyridine-2-carboxylic acid amide 

Downstream Products

• 51674-90-9 4-hydrazinopyrido(3,2-d)pyrimidine 
• 1420618-60-5 C₂₈H₂₃N₇O 
• 1420619-03-9 C₂₉H₂₃N₇O 
• 1420618-39-8 C₂₄H₁₈ClN₅O 
• 1362850-22-3 N-[(R)-1-(8-chloro-2-phenylquinolin-3-yl)-2,2,2-trifluoroethyl]pyrido[3,2-d]pyrimidin-4-ylamine 
• 1304513-59-4 2-(pyrido[3,2-d]pyrimidin-4-ylamino)benzoic acid 
• 50608-99-6 3-amino-pyridine-2-carboxylic acid amide 
• 171347-62-9 4-anilinopyrido[3,2-d]pyrimidine mesylate 

Relevant academic research and scientific papers

Syntheses of Some Azolopyridopyrimidines

Syntheses of isomeric azolopyridopyrimidines are described.As starting material the corresponding pyridopyrimidines were used.It could be established that in many cases a transformation of a functional group with the purpose to form an annelated five-membered ring proceeded with ring opening at the pyrimidine part.Subsequent ring closure with one carbon synthons gave then the desired tricyclic heterocycles. - Keywords: Cyclization with C-N and N-N bond formation; Tricyclic heterocyclic compounds

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

Following the discovery of the very high inhibitory ability of the 4-[(3-bromophenyl)amino]-quinazolines against the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (e.g., 3, IC50 0.029 nM), four series of related pyrido[d]pyrimidines bearing electron-donating groups at the 6- or 7-positions have been synthesized and evaluated. The compounds were prepared by nucleophilic substitution of the corresponding 6- and 7-fluoro analogues. While members of all series showed potent inhibitory activity against isolated EGFR, there were important differences between the different isomeric pyrido[d]pyrimidines and the parent quinazolines. Overall, the [3,4-d] and [4,3-d] series were the most potent, followed by the [3,2-d] compounds, with the [2,3-d] analogues being least active. Whereas in the parent quinazoline series the addition of steric bulk to a 6- or 7-NH2 substituent (i.e., NHMe and NMe2 groups) dramatically decreased potency, no such trend was discernable in the [3,2-d] series. Furthermore, in the 7-substituted pyrido[4,3-d]- and 6-substituted pyrido[3,4-d]pyrimidine series, and to a limited extent in the 7-substituted pyrido[2,3-d] series, such substitution increased potency dramatically, to the extent that the 7-(methylamino)pyrido[4,3-d]pyrimidine (5f) (IC50 0.13 nM) and 6-(methylamino)pyrido[3,4-d]pyrimidine (7f) (IC50 0.008 nM) constitute important new leads. Selected compounds were evaluated for their ability to inhibit EGFR autophosphorylation in A431 cells, and a positive quantitative correlation was found between this activity and inhibitory activity against the isolated enzyme.

Ring-Opening Reactions of Triazolo- and Tetrazolo-Pyridopyrimidines or Quinazolines with some Carbon Nucleophiles

Syntheses of some new pyridotriazolo- and pyridotetrazolopyrimidines are described.These tricyclic systems and tetrazoloquinazoline react with some carbon nucleophiles, generated from compounds with reactive methylene groups, exclusively at position 2 of